Tesamorelin
FDA ApprovedAlso known as: Egrifta, TH9507
Growth Hormone SecretagogueLast reviewed: April 28, 2026
A synthetic analog of growth hormone-releasing hormone (GHRH) that is FDA-approved for HIV-associated lipodystrophy. One of the few peptides with a clear FDA-approved indication, making it a useful reference point for the broader GHRH analog class.
Mechanism of Action
Binds to GHRH receptors on the pituitary gland, stimulating pulsatile GH release. Reduces visceral adipose tissue (VAT) through GH-mediated lipolysis. Maintains the natural pulsatile pattern of GH secretion, preserving feedback mechanisms.
Common Uses
- HIV-associated lipodystrophy (FDA-approved)
- Visceral fat reduction
- Metabolic health improvement
- Growth hormone optimization (off-label)
- Cognitive function (emerging research in older adults)
Known Risks
- Injection site reactions (common)
- Fluid retention and edema
- Arthralgia (joint pain)
- Potential glucose metabolism effects
- Contraindicated in active malignancy
Regulatory Status
FDA-approved as Egrifta (tesamorelin for injection) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Also available through compounding pharmacies for off-label use with a physician prescription.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (Egrifta — FDA-approved)
Typical Dose
2 mg
Frequency
Once daily
Cycle Length
Ongoing for approved indication; 12–26 weeks for off-label use
Inject into abdomen. FDA-approved dose for HIV lipodystrophy. Off-label use for GH optimization follows similar dosing. Longer half-life than Sermorelin — once daily dosing is sufficient.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.